Date: 2012-11-29
Type of information: Commercialisation agreement
Compound: Veregen® ointment (made from the extract of green tea leaves - catechins)
Company: Medigene (Germany) Nordic Pharma (France - Sweden)
Therapeutic area: Infectious diseases - Gynecology - Women's health
Type agreement: commercialisation
Action mechanism:
Disease: genital warts
Details: Medigene and the pharmaceutical company, Nordic Pharma, have entered into an exclusive agreement for the supply and marketing of Veregen® for the treatment of genital warts in the Czech Republic, Slovakia, Poland, Hungary, the Baltic Countries, Georgia and the Commonwealth of Independent States (CIS), which include Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Ukraine, and Uzbekistan. Medigene will benefit from milestone payments and double-digit royalties on sales of Veregen® in these countries, as well as certain payments related to the manufacture and supply of the finished product.
Nordic Pharma is planning to launch Veregen® in the Czech Republic, Slovakia, Poland and Hungary during 2013. Marketing authorization applications for the other countries are in preparation.
After conclusion of this agreement, marketing partnerships for Veregen® now exist for all 17 countries included in the second wave of the European approval procedure, as well as for numerous other markets. Veregen® is already being marketed in the USA (by Fougera), Germany, Austria and Switzerland (by Abbott), and Spain (by Bial). Marketing authorizations in additional countries are granted or expected within the next few months. Medigene has entered into several marketing partnerships for Veregen® across Europe, Asia, and America and is planning to continue this global licensing strategy to further exploit the market potential of the product.
Financial terms:
Latest news:
